Photo Credit: iStock.com/libre de droit

The following is a summary of “Initial development and validation of a disease-specific resilience measure for inflammatory bowel disease: the RISE-IBD instrument,” published in the May 2025 issue of BMC Gastroenterology by Mendiolaza et al. 

Inflammatory bowel diseases (IBDs) significantly impacted well-being and QoL, yet no disease-specific tool existed to accurately measure resilience in this context.  

Researchers conducted a retrospective study to psychometrically validate the newly developed Resilience Scale for IBD (RISE-IBD).  

They developed a preliminary 17-item scale based on a qualitative study involving focus group discussions with individuals with IBD, input from Inflammatory bowel diseases healthcare providers, and a review of 2 validated resilience measures. In this cross-sectional study, the scale’s reliability, validity, and internal consistency was evaluated in a sample of 91 individuals with IBD.  

The results showed that the 17-item RISE-IBD was refined to a 14-item scale. The revised RISE-IBD, covering 4 domains (Disease Acceptance, Self-Reliance, Flexibility, and Persistence), had strong internal consistency (Cronbach’s α = 0.82) and high test-retest reliability (r = 0.91). It showed significant positive correlations with the Connor-Davidson Resilience Scale (r = 0.74), Brief Resilience Scale (BRS) (r = 0.59), and the Inflammatory Bowel Disease Questionnaire (τ = 0.33). Negative associations were observed with psychological distress from the Brief Symptom Inventory (τ = -0.36) and disability levels from the IBD Disability Index (IBD DI) (τ = -0.30).  

Investigators concluded that the RISE-IBD was a psychometrically sound tool for measuring resilience in individuals with IBD. 

Source: bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-025-03971-3